# OnCo record paper-monaleesa-2-n-engl-j-med-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-monaleesa-2-n-engl-j-med-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-monaleesa-2-n-engl-j-med-2016" ;
  schema:name "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer"@en ;
  schema:description "Published report from the MONALEESA-2 trial registered as NCT01958021, in New England Journal of Medicine (2016), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-monaleesa-2-n-engl-j-med-2016/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa1609709>, <https://pubmed.ncbi.nlm.nih.gov/27717303/>, <https://europepmc.org/article/MED/27717303>, <https://clinicaltrials.gov/study/NCT01958021> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1056/nejmoa1609709> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Hortobagyi GN, Stemmer SM, Burris HA, et al." ;
  onco:trials <https://onco.cc/trials/monaleesa-2/> ;
  onco:journals <https://onco.cc/journals/nejm/> .